the vaccine efficacy they found, of 95.6%, reflects that reduction of disease among those who received a booster shot versus those who did not. These are the first results from a randomized, controlled Covid-19 vaccine booster trial, the companies said, and they reflect a period when the highly contagious Delta variant was prevalent.
"In addition to our efforts to increase global access and uptake among the unvaccinated, we believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic," Bourla said."We look forward to sharing these data with health authorities and working together to determine how they can be used to support the rollout of booster doses around the world.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: